27639826|t|Peptide -based vaccination against OPN integrin binding sites does not improve cardio-metabolic disease in mice
27639826|a|Obesity causes insulin resistance via a chronic low-grade inflammation. This inflammation is characterized by elevated pro-inflammatory markers and macrophage accumulation in the adipose tissue (AT). AT inflammation is a key factor causing insulin resistance and thus type 2 diabetes, both linked to atherosclerotic cardiovascular disease. Osteopontin (OPN), a well-known inflammatory cytokine, is involved in obesity -linked complications including AT inflammation, insulin resistance, atherosclerosis and CVD. During inflammation, OPN is proteolytically cleaved by matrix metalloproteinases or thrombin leading to increased OPN activity. Therefore, OPN provides a new interesting target for immunological prevention and treatment of obesity -associated diseases. The aim of our study was to evaluate peptide -based vaccines against integrin binding sites of OPN and to examine whether these active immunotherapies are functional in reducing metabolic tissue inflammation, insulin resistance, and atherosclerosis in a cardio-metabolic (Ldlr (-/-) mice) and a diet -induced obesity model (WT mice). However, atherosclerosis, insulin resistance and AT inflammation were not diminished after treatment with OPN -derived peptides in murine models. Lack of efficacy was based on a failure to induce antibodies capable to bind epitopes in the context of functional OPN protein. In conclusion, our data point to unexpected challenges in the immunotherapeutic targeting of adhesive motives, such as RGD containing sequences, on endogenous proteins.
27639826	0	7	Peptide	T116	C0030956
27639826	15	26	vaccination	T061	C0042196
27639826	35	38	OPN	T116,T123	C0069676
27639826	39	47	integrin	T116,T129,T192	C0021701
27639826	48	61	binding sites	T192	C0005456
27639826	79	103	cardio-metabolic disease	T047	C0012634
27639826	107	111	mice	T015	C0026809
27639826	112	119	Obesity	T047	C0028754
27639826	127	145	insulin resistance	T046	C0021655
27639826	160	169	low-grade	T080	C1282907
27639826	170	182	inflammation	T046	C0021368
27639826	189	201	inflammation	T046	C0021368
27639826	231	247	pro-inflammatory	T033	C0243095
27639826	248	255	markers	T201	C0005516
27639826	260	270	macrophage	T025	C0024432
27639826	271	283	accumulation	T033	C4055506
27639826	291	305	adipose tissue	T024	C0001527
27639826	307	309	AT	T024	C0001527
27639826	312	327	AT inflammation	T047	C0030326
27639826	352	370	insulin resistance	T046	C0021655
27639826	380	395	type 2 diabetes	T047	C0011860
27639826	412	450	atherosclerotic cardiovascular disease	T047	C0004153
27639826	452	463	Osteopontin	T116,T123	C0069676
27639826	465	468	OPN	T116,T123	C0069676
27639826	484	496	inflammatory	T169	C0333348
27639826	497	505	cytokine	T116,T129	C0079189
27639826	522	529	obesity	T047	C0028754
27639826	538	551	complications	T046	C0009566
27639826	562	577	AT inflammation	T047	C0030326
27639826	579	597	insulin resistance	T046	C0021655
27639826	599	614	atherosclerosis	T047	C0004153
27639826	619	622	CVD	T047	C0007222
27639826	631	643	inflammation	T046	C0021368
27639826	645	648	OPN	T116,T123	C0069676
27639826	652	667	proteolytically	T044	C0597304
27639826	668	675	cleaved	T082	C0205242
27639826	679	704	matrix metalloproteinases	T116,T126	C0623362
27639826	708	716	thrombin	T116,T121,T126	C0040018
27639826	728	737	increased	T081	C0205217
27639826	738	741	OPN	T116,T123	C0069676
27639826	763	766	OPN	T116,T123	C0069676
27639826	794	800	target	T169	C1521840
27639826	805	818	immunological	T169	C0205470
27639826	819	829	prevention	T080	C2700409
27639826	834	843	treatment	T061	C0087111
27639826	847	854	obesity	T047	C0028754
27639826	867	875	diseases	T047	C0012634
27639826	881	884	aim	T078	C1947946
27639826	892	897	study	T062	C2603343
27639826	905	913	evaluate	T058	C0220825
27639826	914	921	peptide	T116	C0030956
27639826	929	937	vaccines	T121,T129	C0042210
27639826	946	954	integrin	T116,T129,T192	C0021701
27639826	955	968	binding sites	T192	C0005456
27639826	972	975	OPN	T116,T123	C0069676
27639826	1012	1027	immunotherapies	T061	C0021083
27639826	1032	1042	functional	T169	C0205245
27639826	1046	1054	reducing	T080	C0392756
27639826	1055	1064	metabolic	T169	C0311400
27639826	1065	1071	tissue	T024	C0040300
27639826	1072	1084	inflammation	T046	C0021368
27639826	1086	1104	insulin resistance	T046	C0021655
27639826	1110	1125	atherosclerosis	T047	C0004153
27639826	1131	1147	cardio-metabolic	T047	C0012634
27639826	1149	1153	Ldlr	T028	C1366529
27639826	1160	1164	mice	T015	C0026809
27639826	1172	1176	diet	T168	C0012155
27639826	1186	1193	obesity	T047	C0028754
27639826	1194	1199	model	T050	C0012644
27639826	1201	1203	WT	T028	C1883559
27639826	1204	1208	mice	T015	C0026809
27639826	1220	1235	atherosclerosis	T047	C0004153
27639826	1237	1255	insulin resistance	T046	C0021655
27639826	1260	1275	AT inflammation	T047	C0030326
27639826	1302	1311	treatment	T061	C0087111
27639826	1317	1320	OPN	T116,T123	C0069676
27639826	1330	1338	peptides	T116	C0030956
27639826	1342	1348	murine	T015	C0026809
27639826	1349	1355	models	T050	C0012644
27639826	1357	1361	Lack	T080	C0332268
27639826	1365	1373	efficacy	T080	C1280519
27639826	1389	1396	failure	T169	C0231174
27639826	1400	1406	induce	T169	C0205263
27639826	1407	1417	antibodies	T116,T129	C0003241
27639826	1434	1442	epitopes	T129	C0003316
27639826	1461	1471	functional	T169	C0205245
27639826	1472	1475	OPN	T116,T123	C0069676
27639826	1476	1483	protein	T116,T123	C0033684
27639826	1547	1564	immunotherapeutic	T061	C0021083
27639826	1565	1574	targeting	T169	C1521840
27639826	1604	1628	RGD containing sequences	T116,T123	C0052350
27639826	1633	1643	endogenous	T169	C0205227
27639826	1644	1652	proteins	T116,T123	C0033684